Abstract：
BACKGROUND: Women with menopausal transition (MT) have an elevated risk of experiencing common mental health diagnoses (CMHD: depression or anxiety). There is no recent data comparing the rate, and treatment, of CMHD between men and women.
METHODS: In this population-based study, incidence rates (IR) per 100 person-years-at-risk (PYAR) for men and women ≥45 years registered with an UK primary care practice between 2010 and 2021 were estimated. Incidence rate ratios (IRR) with 95 % confidence intervals (CIs) of CMHD were estimated using men as a reference. We measured first prescriptions for psychotropic medications received within 12 months after CMHD. For selective serotonin reuptake inhibitors (SSRIs) /selective norepinephrine reuptake inhibitors (SNRIs), we measured the IR of prescribing per 100 PYAR, by 10-year bands. Proportion of SSRIs/SNRIs prescribing was estimated per 100 persons.
RESULTS: Rates of anxiety and depressive disorders were 1.68 and 1.69 per 100 PYAR in women aged 45-54 years-old compared to 0.91 and 1.20 per 100 PYAR in men, with IRR of 1.84 (95 % CI 1.72-1.97) and 1.44 (1.35-1.53) respectively. SSRIs/SNRIs were the most prescribed medication; in 2021, IRs for SSRIs/SNRIs were 13.4 per 100 PYAR in both sexes. In 2021, the proportion of SSRIs/SNRIs prescribing was 50.67 per 100 women and 41.91 per 100 men.
CONCLUSIONS: MT is assumed based on women\'s age as menopause onset is rarely recorded in primary care databases.
CONCLUSIONS: Women ≥45 years experienced more CMHD compared to men, especially 45-54 years-olds, which coincides with MT. The proportion of SSRIs/SNRIs prescribing was higher in women.
METHODS: In this population-based study, incidence rates (IR) per 100 person-years-at-risk (PYAR) for men and women ≥45 years registered with an UK primary care practice between 2010 and 2021 were estimated. Incidence rate ratios (IRR) with 95 % confidence intervals (CIs) of CMHD were estimated using men as a reference. We measured first prescriptions for psychotropic medications received within 12 months after CMHD. For selective serotonin reuptake inhibitors (SSRIs) /selective norepinephrine reuptake inhibitors (SNRIs), we measured the IR of prescribing per 100 PYAR, by 10-year bands. Proportion of SSRIs/SNRIs prescribing was estimated per 100 persons.
RESULTS: Rates of anxiety and depressive disorders were 1.68 and 1.69 per 100 PYAR in women aged 45-54 years-old compared to 0.91 and 1.20 per 100 PYAR in men, with IRR of 1.84 (95 % CI 1.72-1.97) and 1.44 (1.35-1.53) respectively. SSRIs/SNRIs were the most prescribed medication; in 2021, IRs for SSRIs/SNRIs were 13.4 per 100 PYAR in both sexes. In 2021, the proportion of SSRIs/SNRIs prescribing was 50.67 per 100 women and 41.91 per 100 men.
CONCLUSIONS: MT is assumed based on women\'s age as menopause onset is rarely recorded in primary care databases.
CONCLUSIONS: Women ≥45 years experienced more CMHD compared to men, especially 45-54 years-olds, which coincides with MT. The proportion of SSRIs/SNRIs prescribing was higher in women.
摘要：
背景：绝经过渡期（MT）的女性经历常见的心理健康诊断（CMHD：抑郁或焦虑）的风险增加。没有最近的数据比较这个比率，和治疗,男性和女性之间的CMHD。
方法：在这项基于人群的研究中，我们估算了2010年至2021年在英国初级保健机构登记的≥45岁男性和女性每100人年高危人群(PYAR)的发病率(IR).以男性为参考，估计CMHD的发生率比率（IRR）和95％置信区间（CIs）。我们测量了CMHD后12个月内接受的第一批精神药物处方。对于选择性5-羟色胺再摄取抑制剂（SSRIs）/选择性去甲肾上腺素再摄取抑制剂（SNRIs），我们测量了每100PYAR的处方IR，十年乐队SSRIs/SNRIs处方的比例估计为每100人。
结果：45-54岁女性的焦虑和抑郁障碍发生率为1.68和1.69/100PYAR，而男性为0.91和1.20/100PYAR。IRR分别为1.84（95%CI1.72-1.97）和1.44（1.35-1.53）。SSRIs/SNRIs是处方最多的药物；2021年，男女SSRIs/SNRIs的IRs为每100PYAR13.4。2021年，SSRIs/SNRIs处方的比例为每100名女性50.67人，每100名男性41.91人。
结论：MT是基于女性的年龄假设的，因为初级保健数据库中很少记录更年期的发作。
结论：与男性相比，≥45岁的女性经历了更多的CMHD，尤其是45-54岁的年轻人,这与MT相吻合。女性处方SSRIs/SNRIs的比例较高。
方法：在这项基于人群的研究中，我们估算了2010年至2021年在英国初级保健机构登记的≥45岁男性和女性每100人年高危人群(PYAR)的发病率(IR).以男性为参考，估计CMHD的发生率比率（IRR）和95％置信区间（CIs）。我们测量了CMHD后12个月内接受的第一批精神药物处方。对于选择性5-羟色胺再摄取抑制剂（SSRIs）/选择性去甲肾上腺素再摄取抑制剂（SNRIs），我们测量了每100PYAR的处方IR，十年乐队SSRIs/SNRIs处方的比例估计为每100人。
结果：45-54岁女性的焦虑和抑郁障碍发生率为1.68和1.69/100PYAR，而男性为0.91和1.20/100PYAR。IRR分别为1.84（95%CI1.72-1.97）和1.44（1.35-1.53）。SSRIs/SNRIs是处方最多的药物；2021年，男女SSRIs/SNRIs的IRs为每100PYAR13.4。2021年，SSRIs/SNRIs处方的比例为每100名女性50.67人，每100名男性41.91人。
结论：MT是基于女性的年龄假设的，因为初级保健数据库中很少记录更年期的发作。
结论：与男性相比，≥45岁的女性经历了更多的CMHD，尤其是45-54岁的年轻人,这与MT相吻合。女性处方SSRIs/SNRIs的比例较高。
